SCHEMBL2526264

SCHEMBL2526264

COc1ccc(CNC(=O)c2ccccc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.83
RAB9A P51151 4/20 0.83
KMT2A Q03164 2/20 0.71
MEN1 O00255 1/20 0.71
EPHX2 P34913 1/20 0.71
NR1H4 Q96RI1 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
ALDH1A1 P00352 2/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
HPGD P15428 2/20 0.67
CYP1A2 P05177 1/20 0.66
CYP2D6 P10635 1/20 0.66
CYP2C9 P11712 1/20 0.66
ALOX12 P18054 1/20 0.66
CYP2C19 P33261 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
CXCR3 P49682 1/20 0.65
PPARG P37231 1/20 0.65
MAPK14 Q16539 1/20 0.65
HDAC1 Q13547 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918147 0.94 NPC1 (0.83) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL9416606 0.92 NPC1 (0.82) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL11761142 0.92 NPC1 (0.82) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL5331526 0.91 MMP13 (0.74) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL1926263 0.91 NPC1 (1.00) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL26101164 0.89 NPC1 (0.80) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL8936384 0.89 HPGD (0.69) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL5331977 0.89 MMP13 (0.76) NPC1RAB9AKMT2AMEN1EPHX2
SCHEMBL1926645 0.87 NPC1 (0.78) NPC1RAB9AEPHX2NR1H4ALDH1A1
SCHEMBL20804653 0.87 NPC1 (0.70) NPC1RAB9AKMT2AMEN1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4249551-A None JP disclosed
CN-118005468-B Method for synthesizing N-alkylated amide compound by catalyzing alcohols and nitriles with nitrogen-carbon material 常州大学 2026-05-19 CN disclosed
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
CN-118005468-A Method for synthesizing N-alkylated amide compound by catalyzing alcohols and nitriles with nitrogen-carbon material 常州大学 2024-05-10 CN disclosed
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2023-04-27 US disclosed
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds AERIE PHARMACEUTICALS, INC. (US) 2022-04-26 US disclosed
CN-114292247-A Disulfide compound and method for catalyzing benzyl oxidation of alkyl aromatic compound by using disulfide compound 大连理工大学 2022-04-08 CN disclosed
CN-109824465-B Method for synthesizing amide by amine oxide catalyzed by bipyridine manganese catalyst 陕西师范大学 2022-01-04 CN disclosed
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS ALCON INC. (CH) 2021-01-07 US disclosed
WO-2019174279-A1 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS THE HONG KONG POLYTECHNIC UNIVERSITY (CN) 2019-09-19 WO disclosed
EP-2480530-A1 ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
US-8039669-B2 Catalytic metathesis of secondary amides WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-10-18 US disclosed
WO-2011033099-A1 ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20090299098-A1 Catalytic Metathesis of Secondary Amides WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-12-03 US disclosed
EP-0548217-B1 PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES BUCHARDT OLE (DK) 1997-04-09 EP disclosed
US-5580751-A REACTING A PEPTIDE WITH A NUCLEOPHILIC AMINE IN THE PRESENCE OF TRYPSIN OR A CARBOXYPEPIDASE; NONENZYMATICALLY CLEAVING TO FORM THE PRODUCT CARLSBERG A/S (DK) 1996-12-03 US disclosed
EP-0548217-A1 PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES. BUCHARDT OLE (DK) 1993-06-30 EP disclosed
JP-H04249551-A RUBBER COMPOSITION SUMITOMO CHEM CO LTD 1992-09-04 JP disclosed
WO-1992005271-A1 PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES BUCHARDT OLE (DK) 1992-04-02 WO disclosed
EP-0300526-A2 Antiviral pharmaceutical compositions containing cyclodextrins JANSSEN PHARMACEUTICA N.V. (BE) 1989-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002253-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK NPC1 2104/4885RAB9A 541/4885KMT2A 1750/4885
US-20090299098-A1 Catalytic Metathesis of Secondary Amides NAAA, NAT1, NAT10 NPC1 2288/4885RAB9A 510/4885KMT2A 760/4885
US-12018012-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK NPC1 2104/4885RAB9A 541/4885KMT2A 1750/4885
US-11312700-B2 Aryl cyclopropyl-amino-isoquinolinyl amide compounds UACA, HRAS, MYLK NPC1 2104/4885RAB9A 541/4885KMT2A 1750/4885
US-20230130470-A1 ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS UACA, HRAS, MYLK NPC1 2104/4885RAB9A 541/4885KMT2A 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.